Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

277 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.
Schöffski P, Wozniak A, Escudier B, Rutkowski P, Anthoney A, Bauer S, Sufliarsky J, van Herpen C, Lindner LH, Grünwald V, Zakotnik B, Lerut E, Debiec-Rychter M, Marréaud S, Lia M, Raveloarivahy T, Collette S, Albiges L. Schöffski P, et al. Among authors: van herpen c. Eur J Cancer. 2017 Dec;87:147-163. doi: 10.1016/j.ejca.2017.10.014. Epub 2017 Nov 14. Eur J Cancer. 2017. PMID: 29149761 Clinical Trial.
Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours.
van Cruijsen H, Voest EE, Punt CJ, Hoekman K, Witteveen PO, Meijerink MR, Puchalski TA, Robertson J, Saunders O, Jürgensmeier JM, van Herpen CM, Giaccone G. van Cruijsen H, et al. Eur J Cancer. 2010 Mar;46(5):901-11. doi: 10.1016/j.ejca.2009.12.023. Epub 2010 Jan 12. Eur J Cancer. 2010. PMID: 20061136 Clinical Trial.
Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041).
van Laarhoven HW, Fiedler W, Desar IM, van Asten JJ, Marréaud S, Lacombe D, Govaerts AS, Bogaerts J, Lasch P, Timmer-Bonte JN, Lambiase A, Bordignon C, Punt CJ, Heerschap A, van Herpen CM. van Laarhoven HW, et al. Among authors: van asten jj, van herpen cm. Clin Cancer Res. 2010 Feb 15;16(4):1315-23. doi: 10.1158/1078-0432.CCR-09-1621. Epub 2010 Feb 9. Clin Cancer Res. 2010. PMID: 20145168 Free article. Clinical Trial.
Factors affecting the unexpected failure of DCE-MRI to determine the optimal biological dose of the vascular targeting agent NGR-hTNF in solid cancer patients.
Desar IM, van Herpen CM, van Asten JJ, Fiedler W, Marreaud S, Timmer-Bonte JN, ter Voert EG, Lambiase A, Bordignon C, Heerschap A, van Laarhoven HW. Desar IM, et al. Among authors: van laarhoven hw, van herpen cm, van asten jj. Eur J Radiol. 2011 Dec;80(3):655-61. doi: 10.1016/j.ejrad.2010.08.045. Epub 2010 Sep 21. Eur J Radiol. 2011. PMID: 20863638
A new, simple and objective prognostic score for phase I cancer patients.
Füssenich LM, Desar IM, Peters ME, Teerenstra S, van der Graaf WT, Timmer-Bonte JN, van Herpen CM. Füssenich LM, et al. Among authors: van der graaf wt, van herpen cm. Eur J Cancer. 2011 May;47(8):1152-60. doi: 10.1016/j.ejca.2010.12.028. Epub 2011 Feb 25. Eur J Cancer. 2011. PMID: 21354785
277 results